BACKGROUND: Psoriasis vulgaris is a chronic autoimmune disease associated with systemic inflammation. Increased levels of numerous cytokines, chemokines, growth factors, and other molecules were found in the skin and in the circulation of psoriatic patients. Alarmins, also known as danger signals, are intracellular proteins, which are released to an extracellular space after infection or damage. They are the markers of cell destructive processes. OBJECTIVE: The aim of the present study was to evaluate the suitability of selected alarmins (HMGB1, IL-33, S100A7, and S100A12) as potential biomarkers of severity of psoriasis and to explore possible relationships between these proteins for the purpose of better understanding their roles in the immunopathology of psoriasis. METHODS: The serum levels of selected alarmins were measured in 63 psoriatic patients and 95 control individuals. The levels were assessed by the ELISA technique using commercial kits. The data were statistically processed with MedCalc version 19.0.5. RESULTS: In psoriatic patients, we found significantly increased levels of HMGB1 (p < 0.05), IL-33 (p < 0.01), S100A7 (p < 0.0001), and S100A12 (p < 0.0001). In addition, we found a significant relationship between HMGB1 and S100A7 (Spearman's rho = 0.276, p < 0.05) in the patients and significant relationship between HMGB1 and IL-33 in the controls (Spearman's rho = 0.416, p < 0.05). We did not find any relationship between observed alarmins and the disease severity. CONCLUSIONS: The alarmins HMGB1, IL-33, S100A7, and S100A12 were significantly elevated in the serum of patients, which states the hypothesis that they play specific roles in the immunopathology of psoriasis. However, we have not yet found a relationship between observed alarmins and the disease severity. The discovery of the relationship between HMGB1 and S100A7 is a novelty that should be studied in the future to further clarify its role and importance.

Clinic of Dermal and Venereal Diseases University Hospital Hradec Kralove Hradec Kralove 500 03 Czech Republic

Institute of Clinical Biochemistry and Diagnostics University Hospital and Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove 500 03 Czech Republic

Institute of Clinical Immunology and Allergology University Hospital and Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove 500 03 Czech Republic

Institute of Hygiene and Preventive Medicine Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove 500 03 Czech Republic

Institute of Pathological Physiology Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove 500 03 Czech Republic

Transfusion Center University Hospital Hradec Kralove Hradec Kralove 500 03 Czech Republic

See more in PubMed

Borska L., Kremlacek J., Andrys C., et al. Systemic inflammation, oxidative damage to nucleic acids, and metabolic syndrome in the pathogenesis of psoriasis. International Journal of Molecular Sciences. 2017;18(11):p. 2238. doi: 10.3390/ijms18112238. PubMed DOI PMC

Lebwohl M. G., Bachelez H., Barker J., et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Journal of the American Academy of Dermatology. 2014;70(5):871–881.e30. doi: 10.1016/j.jaad.2013.12.018. PubMed DOI

Beranek M., Fiala Z., Kremlacek J., et al. Changes in circulating cell-free DNA and nucleosomes in patients with exacerbated psoriasis. Archives of Dermatological Research. 2017;309(10):815–821. doi: 10.1007/s00403-017-1785-5. PubMed DOI

Anderson K. S., Petersson S., Wong J., et al. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. British Journal of Dermatology. 2010;163(5):1085–1089. doi: 10.1111/j.1365-2133.2010.09990.x. PubMed DOI

Nefla M., Holzinger D., Berenbaum F., Jacques C. The danger from within: alarmins in arthritis. Nature Reviews Rheumatology. 2016;12(11):669–683. doi: 10.1038/nrrheum.2016.162. PubMed DOI

Holzinger D., Tenbrock K., Roth J. Alarmins of the S100-family in juvenile autoimmune and auto-inflammatory diseases. Frontiers in Immunology. 2019;10:p. 182. doi: 10.3389/fimmu.2019.00182. PubMed DOI PMC

Bianchi M. E., Manfredi A. A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunological Reviews. 2007;220:35–46. doi: 10.1111/j.1600-065X.2007.00574.x. PubMed DOI

Yang H. Alarmins and immunity. Immunological Reviews. 2017;280(1):41–56. doi: 10.1111/imr.12577. PubMed DOI PMC

Nie Y., Yang D., Oppenheim J. J. Alarmins and antitumor immunity. Clinical Therapeutics. 2016;38(5):1042–1053. doi: 10.1016/j.clinthera.2016.03.021. PubMed DOI PMC

Chan J. K., Roth J., Oppenheim J. J., et al. Alarmins: awaiting a clinical response. The Journal of Clinical Investigation. 2012;122(8):2711–2719. doi: 10.1172/JCI62423. PubMed DOI PMC

Venereau E., De Leo F., Mezzapelle R., Careccia G., Musco G., Bianchi M. E. HMGB1 as biomarker and drug target. Pharmacological Research. 2016;111:534–544. doi: 10.1016/j.phrs.2016.06.031. PubMed DOI

Gohar F., Anink J., Moncrieffe H., et al. S100A12 is associated with response to therapy in juvenile idiopathic arthritis. The Journal of Rheumatology. 2018;45(4):547–554. doi: 10.3899/jrheum.170438. PubMed DOI PMC

Saadah O. I., Al-Harthi S. E., Al-Mughales J. A., Bin-Taleb Y. Y., Baeshen R. S. Serum Interleukin-33 level in Saudi children with inflammatory bowel disease. International Journal of Clinical and Experimental Pathology. 2015;8(12):16000–16006. PubMed PMC

Dumitriu I. E., Baruah P., Manfredi A. A., Bianchi M. E., Rovere-Querini P. HMGB1: an immmune odyssey. Discovery Medicine. 2005;5(28):388–392. PubMed

Strohbuecker L., Koenen H., van Rijssen E., et al. Increased dermal expression of chromatin-associated protein HMGB1 and concomitant T-cell expression of the DNA RAGE in patients with psoriasis vulgaris. Psoriasis: Targets and Therapy. 2019;2019:7–17. doi: 10.2147/PTT.S190507. PubMed DOI PMC

Ye Y., Zeng Z., Jin T., Zhang H., Xiong X., Gu L. The role of high mobility group box 1 in ischemic stroke. Frontiers in Cellular Neuroscience. 2019;13:p. 127. doi: 10.3389/fncel.2019.00127. PubMed DOI PMC

Lu H., Zhang Z., Barnie P. A., Su Z. Dual faced HMGB1 plays multiple roles in cardiomyocyte senescence and cardiac inflammatory injury. Cytokine & Growth Factor Reviews. 2019;47:74–82. doi: 10.1016/j.cytogfr.2019.05.009. PubMed DOI

Sehat M., Talaei R., Dadgostar E., Nikoueinejad H., Akbari H. Evaluating serum levels of IL-33, IL-36, IL-37 and gene expression of IL-37 in patients with psoriasis vulgaris. Iranian Journal of Allergy, Asthma, and Immunology. 2018;17(2):179–187. PubMed

Lloyd C. M. IL-33 family members and asthma – bridging innate and adaptive immune responses. Current Opinion in Immunology. 2010;22(6):800–806. doi: 10.1016/j.coi.2010.10.006. PubMed DOI PMC

Vaccaro M., Cicero F., Mannucci C., et al. IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo. Archives of Dermatological Research. 2016;308(7):527–530. doi: 10.1007/s00403-016-1675-2. PubMed DOI

Anderson K. S., Wong J., Polyak K., Aronzon D., Enerback C. Detection of psoriasin/S100A7 in the sera of patients with psoriasis. The British Journal of Dermatology. 2009;160(2):325–332. doi: 10.1111/j.1365-2133.2008.08904.x. PubMed DOI

Granata M., Skarmoutsou E., Mazzarino M. C., D'Amico F. S100A7 in psoriasis: immunodetection and activation by CRISPR technology. Methods in Molecular Biology. 1929;1929:729–738. doi: 10.1007/978-1-4939-9030-6_45. PubMed DOI

Son E. D., Kim H. J., Kim K. H., et al. S100A7 (psoriasin) inhibits human epidermal differentiation by enhanced IL-6 secretion through IκB/NF-κB signalling. Experimental Dermatology. 2016;25(8):636–641. doi: 10.1111/exd.13023. PubMed DOI

Ye L., Sun P. H., Martin T. A., Sanders A. J., Mason M. D., Jiang W. G. Psoriasin (S100A7) is a positive regulator of survival and invasion of prostate cancer cells. Urologic Oncology. 2013;31(8):1576–1583. doi: 10.1016/j.urolonc.2012.05.006. PubMed DOI

Foell D., Kane D., Bresnihan B., et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology. 2003;42(11):1383–1389. doi: 10.1093/rheumatology/keg385. PubMed DOI

Wilsmann-Theis D., Wagenpfeil J., Holzinger D., et al. Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity. Journal of the European Academy of Dermatology and Venereology. 2016;30(7):1165–1170. doi: 10.1111/jdv.13269. PubMed DOI

Malkic Salihbegovic E., Hadzigrahic N., Cickusic A. J. Psoriasis and metabolic syndrome. Medical Archives. 2015;69(2):85–87. doi: 10.5455/medarh.2015.69.85-87. PubMed DOI PMC

Bergmann C., Strohbuecker L., Lotfi R., et al. High mobility group box 1 is increased in the sera of psoriatic patients with disease progression. Journal of the European Academy of Dermatology and Venereology. 2016;30(3):435–441. doi: 10.1111/jdv.13564. PubMed DOI

Uzawa A., Mori M., Masuda S., Muto M., Kuwabara S. CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. Journal of Neurology, Neurosurgery, and Psychiatry. 2013;84(5):517–522. doi: 10.1136/jnnp-2012-304039. PubMed DOI

Zickert A., Palmblad K., Sundelin B., et al. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Research & Therapy. 2012;14(1):p. R36. doi: 10.1186/ar3747. PubMed DOI PMC

Andersson U., Harris H. E. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 2010;1799(1-2):141–148. doi: 10.1016/j.bbagrm.2009.11.003. PubMed DOI

Mitsui A., Tada Y., Takahashi T., et al. Serum IL-33 levels are increased in patients with psoriasis. Clinical and Experimental Dermatology. 2016;41(2):183–189. doi: 10.1111/ced.12670. PubMed DOI

Li J., Liu L., Rui W., et al. New interleukins in psoriasis and psoriatic arthritis patients: the possible roles of interleukin-33 to interleukin-38 in disease activities and bone erosions. Dermatology. 2017;233(1):37–46. doi: 10.1159/000471798. PubMed DOI

Han J. H., Suh C. H., Jung J. Y., et al. Serum levels of interleukin 33 and soluble ST2 are associated with the extent of disease activity and cutaneous manifestations in patients with active adult-onset Still's disease. The Journal of Rheumatology. 2017;44(6):740–747. doi: 10.3899/jrheum.170020. PubMed DOI

Tamagawa-Mineoka R., Okuzawa Y., Masuda K., Katoh N. Increased serum levels of interleukin 33 in patients with atopic dermatitis. Journal of the American Academy of Dermatology. 2014;70(5):882–888. doi: 10.1016/j.jaad.2014.01.867. PubMed DOI

Gambichler T., Bechara F. G., Scola N., Rotterdam S., Altmeyer P., Skrygan M. Serum levels of antimicrobial peptides and proteins do not correlate with psoriasis severity and are increased after treatment with fumaric acid esters. Archives of Dermatological Research. 2012;304(6):471–474. doi: 10.1007/s00403-012-1227-3. PubMed DOI

Batycka-Baran A., Maj J., Wolf R., Szepietowski J. C. The new insight into the role of antimicrobial proteins-alarmins in the immunopathogenesis of psoriasis. Journal of Immunology Research. 2014;2014:10. doi: 10.1155/2014/628289.628289 PubMed DOI PMC

Hegyi Z., Zwicker S., Bureik D., et al. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. The Journal of Investigative Dermatology. 2012;132(5):1416–1424. doi: 10.1038/jid.2011.486. PubMed DOI

Shubbar E., Vegfors J., Carlstrom M., Petersson S., Enerback C. Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Research and Treatment. 2012;134(1):71–80. doi: 10.1007/s10549-011-1920-5. PubMed DOI

Salama R. H., Al-Shobaili H. A., Al Robaee A. A., Alzolibani A. A. Psoriasin: a novel marker linked obesity with psoriasis. Disease Markers. 2013;34(1):33–39. doi: 10.3233/DMA-2012-120945. PubMed DOI PMC

Awad S. M., Attallah D. A., Salama R. H., Mahran A. M., Abu E.-H. E. Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis. Clinical and Experimental Dermatology. 2018;43(3):262–267. doi: 10.1111/ced.13370. PubMed DOI

Takahashi T., Asano Y., Yamashita T., et al. A potential contribution of psoriasin to vascular and epithelial abnormalities and inflammation in systemic sclerosis. Journal of the European Academy of Dermatology and Venereology. 2018;32(2):291–297. doi: 10.1111/jdv.14459. PubMed DOI

Uysal S., Yilmaz F. M., Karatoprak K., Artuz F., Cumbul N. U. The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. European Review for Medical and Pharmacological Sciences. 2014;18(22):3453–3458. PubMed

Kondelkova K., Borska L., Andrys C., et al. Selected inflammatory and metabolic markers in psoriatic patients treated with goeckerman therapy. Mediators of Inflammation. 2015;2015:8. doi: 10.1155/2015/979526.979526 PubMed DOI PMC